Indications for dabrafenib and trametinib

Dabrafenib and trametinib are commonly used to treat advanced or metastatic melanoma caused by BRAF V600 mutations. These two drugs are targeted therapies that inhibit abnormal signaling pathways and prevent the growth and spread of cancer cells. In clinical practice, the combination of dabrafenib and trametinib has been proven to have a significant therapeutic effect on this type of melanoma patients, which can significantly extend the patient's survival, slow down the progression of the disease, and improve the overall treatment response rate. Therefore, the combination of dabrafenib and trametinib has become one of the standard treatment options for the treatment of advanced or metastatic melanoma caused by BRAF V600 mutations.